0.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Enzolytics
Its shares trade under the ticker ENZC. It has been listed since 23 February 2009. In the fiscal year to 31 December 2023, it reported revenue of $52,796 and a net loss of $2.2m. At that date it held total assets of $361.7m and shareholders' equity of −$3.6m.
Enzolytics, Inc. operates as a development stage company. The company is headquartered in Monrovia California, California. The company went IPO on 2009-02-23. The firm is focused on commercialization of its proprietary proteins for the treatment of human immunodeficiency viruses (HIV)/ acquired immunodeficiency syndrome (AIDS). The company is also focused on exploring/developing additional applications of its novel immunotherapy compounds. Its flagship compound, Immune Therapeutic Vaccine-1 (ITV-1) is a suspension of Inactivated Pepsin Fraction (IPF). IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 23 Feb 2009
- Employees
- 2
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Enzolytics Inc possesses a robust intellectual property portfolio that includes patents, trademarks, and copyrights. This provides the company with a significant competitive advantage and ensures the protection of its innovative solutions and products in the biotech industry.
- Enzolytics Inc is known for its cutting-edge biotechnology solutions that are designed to address various medical challenges. These innovative products have the potential to disrupt existing treatment options and offer significant improvements in patient care.
Weaknesses
- Enzolytics Inc heavily relies on research and development activities, which can be expensive and time-consuming. Delays in product development or unsuccessful outcomes from ongoing research projects could negatively impact the company's profitability and market position.
- Enzolytics Inc currently has a limited market presence, which can restrict its customer base and revenue generation opportunities. Expanding its market reach and establishing partnerships with distribution channels would be crucial to overcome this weakness.
Opportunities
- The biotech industry is witnessing rapid growth globally, with increasing demand for innovative solutions to various healthcare challenges. Enzolytics Inc can capitalize on this opportunity by leveraging its expertise and expanding its product offerings in emerging markets.
- Forming strategic partnerships and collaborations with other established players in the biotech sector can provide Enzolytics Inc with access to additional resources, expertise, and distribution channels. This could facilitate faster market penetration and enhance the company's competitive advantage.
Threats
- The biotech industry is highly competitive, with numerous companies vying for market share. Enzolytics Inc faces the threat of competing against well-established biotech giants who possess significant financial resources and established customer networks.
- Compliance with regulatory requirements and obtaining necessary approvals can be a complex and time-consuming process in the biotech industry. Enzolytics Inc must remain vigilant and ensure full compliance with applicable regulations to mitigate potential risks and delays in launching new products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.